Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study

• Published in: Infection 2012-02, Vol.40 (1), p.69-75
• Main Authors: Bonora, S., Calcagno, A., Cometto, C., Fontana, S., Aguilar, D., D’Avolio, A., Gonzalez de Requena, D., Maiello, A., Dal Conte, I., Lucchini, A., Di Perri, G.
• Format: Article
• Language: English
• Subjects: Adult; Antiretroviral agents; Antiretroviral Therapy, Highly Active; Brief Report; CD4 Lymphocyte Count; Family Medicine; Female; General Practice; HIV - drug effects; HIV - immunology; HIV Envelope Protein gp41 - administration & dosage; HIV Envelope Protein gp41 - therapeutic use; HIV Fusion Inhibitors - administration & dosage; HIV Fusion Inhibitors - therapeutic use; HIV Infections - drug therapy; HIV Infections - virology; Humans; Infectious Diseases; Internal Medicine; Italy; Male; Medicine; Medicine & Public Health; Middle Aged; Peptide Fragments - administration & dosage; Peptide Fragments - therapeutic use; Pilot Projects; Proteinase inhibitors; Reverse Transcriptase Inhibitors - administration & dosage; Reverse Transcriptase Inhibitors - therapeutic use; Ritonavir; Viral Load
• ISSN: 0300-8126; 1439-0973
• DOI: 10.1007/s15010-011-0223-4

Objectives To evaluate whether the addition of enfuvirtide to standard highly active antiretroviral therapy (HAART) could confer immunovirological benefits in human immunodeficiency virus (HIV)-infected very late presenters. The current study is an open comparative therapeutic trial of standard protease inhibitor (PI)-based HAART ± additional enfuvirtide in treatment-naïve deeply immunologically impaired HIV-positive patients. Methods Very late presenters (CD4